HRS-5965 capsule

DRUG3 trials

Sponsors

Chengdu Suncadia Medicine Co., Ltd.

Conditions

Hemolytic AnemiaParoxysmal Nocturnal Hemoglobinuria

Phase 1

A Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Study, and QT Interval Study of HRS-5965 Capsules in Healthy Subjects

CompletedNCT06684041

Chengdu Suncadia Medicine Co., Ltd.Hemolytic Anemia

Start: 2024-11-09End: 2025-04-07Updated: 2025-07-04

Phase 3

A Study to Evaluate the Efficacy and Safety of Oral HRS-5965 in Adult Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy

CompletedNCT06593938

Chengdu Suncadia Medicine Co., Ltd.Paroxysmal Nocturnal Hemoglobinuria

Start: 2024-10-25End: 2025-07-31Updated: 2025-09-11

Efficacy and Safety of HRS-5965 in Patients With PNH Who Are Still Anemia After Anti-C5 Antibody Treatment

CompletedNCT06715943

Chengdu Suncadia Medicine Co., Ltd.Paroxysmal Nocturnal Hemoglobinuria

Start: 2025-01-07End: 2026-01-06Updated: 2026-01-08